SPARC enters into an exclusive worldwide license agreement with Johns Hopkins University, IOCB for hair loss drug
SCD-153 is a first-in-class topical drug for the treatment of alopecia areata developed jointly by SPARC, JHU and IOCB.
Mumbai: Sun Pharma Advanced Research Company Ltd. has announced that it has entered into an agreement with Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) (Licensors) to exclusively license SCD-153 including all patents and patent applications owned or controlled by licensors.
SPARC had evaluated SCD-153 under a Material Transfer Agreement (MTA) after which it entered into an Option to License Agreement with the licensors. SPARC’s IND was approved by Drug Controller General of India (DCGI).
Under the terms of the agreement, the licensors are eligible for upfront payment, milestone payments contingent upon the achievement of regulatory and sales milestones, as well as tiered royalties on sales.
“The licensing of SCD-153 marks another successful collaboration between SPARC and an academic institute under our outreach program with academia. Topical SCD-153, upon successful development, can provide an important option to clinicians and patients for the treatment of Alopecia Areata " said Anil Raghavan, CEO of SPARC.
Read also: Sun Pharma, SPARC collaborate for commercialization of phenobarbital for injection in US
SCD-153 is a first-in-class topical drug for the treatment of alopecia areata developed jointly by SPARC, JHU and IOCB. SCD-153 inhibits pro-inflammatory pathways such as TET2, IFN-β, IkBz mediated IL-6 and inflammasome pathways. It also stimulates the antioxidant KEAP1/Nrf2 pathway. In-vivo experiments have established that SCD-153 hastens the transition of hair follicles from the telogen to anagen phase leading to hair growth.
Read also: SPARC concludes enrolment in global Phase 2 study of Vodobatinib in early Parkinson's disease
